Treatment - Page 22 of 471 Posts on Medivizor
Navigation Menu

Treatment Posts on Medivizor

Adding pembrolizumab before and after surgery for early triple-negative breast cancer

Adding pembrolizumab before and after surgery for early triple-negative breast cancer

Posted by on Jun 30, 2022 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate pembrolizumab (Keytruda) before and after surgery in patients with early triple-negative breast cancer (TNBC).  This study concluded that the addition of pembrolizumab to chemotherapy before surgery and after surgery for TNBC improved the survival without complications from TNBC in these...

Read More

Aromatase inhibitors versus tamoxifen for premenopausal women with hormone positive early-stage breast cancer treated with ovarian suppression.

Aromatase inhibitors versus tamoxifen for premenopausal women with hormone positive early-stage breast cancer treated with ovarian suppression.

Posted by on Jun 26, 2022 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness of aromatase inhibitors (AIs) versus tamoxifen (Nolvadex) for the treatment of premenopausal patients with estrogen receptor-positive (ER+) early-stage breast cancer (BC) treated with ovarian suppression. The data showed that AIs significantly reduced the risk of BC recurrence compared...

Read More

Evaluating the effectiveness and safety of isatuximab in combination with pomalidomide and low-dose dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma.

Evaluating the effectiveness and safety of isatuximab in combination with pomalidomide and low-dose dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma.

Posted by on Jun 26, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the long-term effectiveness and safety of isatuximab (Sarclisa) in combination with pomalidomide (Pomalyst) and low-dose dexamethasone (Decadron) (Pd) in previously treated patients with relapsed or refractory (r/r) multiple myeloma (MM). The data showed that isatuximab plus Pd combination significantly improved the...

Read More

Evaluating the predictors of cure and overactive bladder syndrome after a mid-urethral sling procedure in women with stress urinary incontinence.

Evaluating the predictors of cure and overactive bladder syndrome after a mid-urethral sling procedure in women with stress urinary incontinence.

Posted by on Jun 26, 2022 in Urinary incontinence | 0 comments

In a nutshell This study evaluated the factors that could predict the cure and overactive bladder (OAB) syndrome after a mid-urethral sling (MUS) procedure in women with stress urinary incontinence (SUI). The study found age and overactivity of the detrusor (bladder) before surgery were independent predictors of persisting/recurrent SUI. OAB before...

Read More

Evaluating the effectiveness and safety of 225Ac-PSMA-617 for the treatment of patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of 225Ac-PSMA-617 for the treatment of patients with metastatic castration-resistant prostate cancer.

Posted by on Jun 26, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of actinium-225 [225Ac]-PSMA-617 (225AcPSMA) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that 225AcPSMA was effective with manageable side effects for these patients. Some background Prostate cancer (PC) often grows in...

Read More

Evaluating the role of vitamin D supplementation in patients with breast cancer receiving doxorubicin chemotherapy.

Evaluating the role of vitamin D supplementation in patients with breast cancer receiving doxorubicin chemotherapy.

Posted by on Jun 26, 2022 in Breast cancer | 0 comments

In a nutshell The study investigated the effects of vitamin D (Vit D) supplementation in patients with early breast cancer receiving doxorubicin (DOX; Adriamycin)-based chemotherapy. The results showed that patients taking DOX plus Vit D had improved heart-related blood markers. Some background The main treatment for early...

Read More

Reviewing chemotherapy and hormonal therapy before prostate surgery in patients with prostate cancer

Reviewing chemotherapy and hormonal therapy before prostate surgery in patients with prostate cancer

Posted by on Jun 14, 2022 in Prostate cancer | 0 comments

In a nutshell The review investigated the effects of neoadjuvant chemo-hormonal therapy (NCHT; chemotherapy and hormonal therapy before surgery) in patients with prostate cancer (PCa). The results showed that compared to patients who received prostate surgery alone, NCHT before prostate surgery improved the oncological outcomes of these...

Read More

Comparing Retzius-sparing and conventional robot-assisted radical prostatectomy for men with localized prostate cancer

Comparing Retzius-sparing and conventional robot-assisted radical prostatectomy for men with localized prostate cancer

Posted by on Jun 5, 2022 in Prostate cancer | 0 comments

In a nutshell This review compared the outcomes of 2 techniques for robotic-assisted radical prostatectomy (RARP; complete removal of the prostate gland using robotic arms): Retzius-sparing (RS)-RARP and conventional (C)-RARP in patients with localized prostate cancer (PCa). The analysis showed that RS-RARP was associated with improved urinary...

Read More

Extending therapy with aromatase inhibitors to 10 years in postmenopausal patients with hormone receptor-positive early-stage breast cancer.

Extending therapy with aromatase inhibitors to 10 years in postmenopausal patients with hormone receptor-positive early-stage breast cancer.

Posted by on Jun 5, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of extending treatment with letrozole (Femara), an aromatase inhibitor, to 10 years in postmenopausal patients with hormone receptor-positive (HR+) early-stage breast cancer (BC). The data showed that extending treatment with letrozole to 10 years significantly improved the...

Read More

Evaluating brentuximab-vedotin with bendamustine combination treatment before transplantation in patients with relapsed/refractory Hodgkin lymphoma

Evaluating brentuximab-vedotin with bendamustine combination treatment before transplantation in patients with relapsed/refractory Hodgkin lymphoma

Posted by on Jun 1, 2022 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of brentuximab-vedotin (Bv; Adcetris) combined with bendamustine (Treanda: B) as salvage treatment in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). This study concluded that this treatment is safe and effective in these patients....

Read More

How effective is an immunomodulatory vaccine against PD-L1 /IDO in combination with nivolumab for the treatment of metastatic melanoma?

How effective is an immunomodulatory vaccine against PD-L1 /IDO in combination with nivolumab for the treatment of metastatic melanoma?

Posted by on Jun 1, 2022 in Melanoma | 0 comments

In a nutshell The study aimed to evaluate the safety and effectiveness of an immunomodulatory IDO/PD-L1 targeting peptide vaccine (IO102/IO103) combined with nivolumab (Opdivo) in patients with metastatic melanoma (MM). The study concluded that the IO102/IO103 vaccine combined with nivolumab is safe and effective in these...

Read More

How effective is non-myeloablative chemotherapy after high-dose methotrexate-based treatment in patients with primary central nervous system lymphoma?

How effective is non-myeloablative chemotherapy after high-dose methotrexate-based treatment in patients with primary central nervous system lymphoma?

Posted by on Jun 1, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of patients with primary central nervous system lymphoma (PCNSL) on high-dose methotrexate (HD-MTX; Otrexup)-based chemotherapy followed by non-myeloablative consolidation therapy. The study showed that HD-MTX-based chemotherapy with non-myeloablative consolidation therapy is an alternative and...

Read More